German Cancer Research Center patents CDK12 inhibitors

Aug. 9, 2023

The German Cancer Research Center has discovered cyclin-dependent kinase 12 (CDK12)/cyclin K inhibitors reported to be useful for the treatment of cancer.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for Sept. 18, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for September 17, 2024.

Big pharma eyes China ‘at forefront of GLP-1 revolution’

BioWorld

Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes – Novo Nordisk A/S’s semaglutide (Wegovy/Ozempic) and Eli Lilly and...

Novo Nordisk seeks to repurpose GLP-1s, again, for the brain

BioWorld

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists (GLP-1RA) market for diabetes and...

Partial epigenetic reprogramming to treat ischemic optic neuropathy

BioWorld

A novel gene therapy that leads to cellular rejuvenation could restore vision after non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma. The...

Upgrade your daily dose of biopharma and medtech news

German Cancer Research Center patents CDK12 inhibitors